Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 3
Submit an article Journal homepage
113
Views
0
CrossRef citations to date
0
Altmetric
Original research

Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014

Ziyan Chena Department of Pharmaceutical Outcomes & Policy (POP), College of Pharmacy, University of Florida, Gainesville, FL, USAView further author information
,
Aram Babcocka Department of Pharmaceutical Outcomes & Policy (POP), College of Pharmacy, University of Florida, Gainesville, FL, USAView further author information
,
Vassiki Sanogoa Department of Pharmaceutical Outcomes & Policy (POP), College of Pharmacy, University of Florida, Gainesville, FL, USAView further author information
,
David R. Nelsonb Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USAView further author information
,
Hong Xiaoc Bristol-Myers Squibb, Lawrenceville, NJ, USAView further author information
&
Vakaramoko Diabya Department of Pharmaceutical Outcomes & Policy (POP), College of Pharmacy, University of Florida, Gainesville, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6251-0773View further author information
ORCID Icon
Pages 409-415 | Received 12 Mar 2021, Accepted 06 May 2021, Published online: 16 Jul 2021

References

  • Patidar KR, Jasmohan SB. Covert and overt hepatic encephalopathy: diagnosis and management. J Clin Exp Hepatol. 2015;13(12):2048–2061.
  • Riordan SM, Roger W. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337(7):473–479.
  • Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081.
  • Conn H, Lieberthal M. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins; 1979.
  • Tapper EB, Henderson JB, Parikh ND, et al. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol Commun. 2019 Sept 6;3(11):1510–1519.
  • Romoli M, Mazzocchetti P, D’Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926–946.
  • Laffi G, La Villa G, Carloni V, et al. Loop diuretic therapy in liver cirrhosis with ascites. J Cardiovasc Pharmacol. 1993;22(Suppl 3):S51–8.
  • Neff G, Zachry W. Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Pharmacoeconomics. 2018;36(7):809–822.
  • Bajaj JS, Wade JB, Gibson DP, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106(9):1646–1653.
  • Nguyen GC, Dorry LS, Paul JT. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol. 2007;5(9):1092–1099.
  • Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25:3–9.
  • Stepanova M, Alita M, Chapy V, et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012;10(9):1034–1041.
  • CPI inflation calculator [Internet]. [cited 2021 Apr 28]. Available from: https://www.bls.gov/data/inflation_calculator.htm
  • Austin PC, Merlo J. Intermediate and advanced topics in multilevel logistic regression analysis. Stat Med. 2017;36(20):3257–3327.
  • Shaheen AA, Nguyen HH, Congly SE, et al. Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 2019;39(5):878–884.
  • Vadhariya A, Chen H, Serna O, et al. A retrospective study of drug utilization and hospital readmissions among medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020;99(16):e19603.
  • Montagnese S, Amato E, Schiff S, et al. A patients’ and caregivers’ perspective on hepatic encephalopathy. Metab Brain Dis. 2012;27(4):567–572.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.